Abstract 2490
Background
ANAM, an oral selective ghrelin receptor agonist, showed benefits for patients with advanced non-small cell lung cancer (NSCLC) and anorexia/cachexia. A clinical trial assessing possible gender effects on ANAM PK/PD in healthy volunteers following a single 25-mg oral ANAM dose reported no significant differences in PK/PD responses (Leese et al, Clin Pharmacol Drug Dev 2015). Given the interest in possible gender effects in cachexia, the effect of gender on ANAM PK/PD in healthy volunteers and NSCLC patients with cachexia receiving the 100-mg ANAM dose intended for therapeutic use was assessed.
Methods
In a phase 1 clinical trial, healthy volunteers received a single ANAM dose and the PK profile was evaluated by non-compartmental methods. Cachectic NSCLC patients from the phase 3 trial ROMANA 1 (NCT01387269) received ANAM once daily up to 12 weeks. Sparse blood samples were collected at steady state from 70 patients consenting to population PK modeling, along with ANAM PK data from phase 1 and 2 studies in healthy subjects and patients. Correlations between gender and predicted individual ANAM PK parameters in patients at steady state were assessed by analysis of variance models. In a separate phase II trial, serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) levels were assessed in NSCLC male and female outpatients receiving ANAM up to 14 weeks.
Results
In healthy volunteers, after dose normalization per body weight, the PK parameters of males and females were similar (Table). In patients with cachexia, no significant correlations were found between gender and predicted ANAM PK parameters at steady state (Table). No gender differences were observed in IGF-1 and IGFBP-3 serum levels.Table:
1784P Gender effect on the main PK parameters of ANAM after single administration in healthy volunteers and at steady state in NSCLC patients with cachexia
Healthy volunteers | ||||
---|---|---|---|---|
Mean (SD) | Males (N = 16) | Females (N = 16) | ||
Cmax, ng/mL | 745.3 (343.3) | 1056.8 (306.6) | ||
Cmax/dose, [ng/mL]/[mg/kg] | 603.5 (286.4) | 703.4 (201.8) | ||
tmax, hr | 1.00 (0.84) | 0.84 (0.43) | ||
AUCinf, ng*hr/mL | 1762.8 (1121.5) | 2715.1 (980.8) | ||
AUCinf/dose, [ng*hr/mL]/[mg/kg] | 1420.7 (855.4) | 1782.4 (598.3) | ||
t1/2,z, hr | 5.66 (2.64) | 7.03 (3.50) | ||
CL/F, L/hr/kg | 0.90 (0.40) | 0.63 (0.23) | ||
Vz/F, L/kg | 6.18 (1.93) | 6.25 (3.81) | ||
NSCLC patients with cachexia | ||||
LS mean | Males (N = 55) | Females (N = 15) | LS mean ratio (90% CI) | p-value |
Cmax,ss, ng/mL | 539.39 | 603.35 | 0.894 (0.633–1.263) | 0.5905 |
AUC0-24,ss, ng*hr/mL | 2432.44 | 2631.32 | 0.924 (0.727–1.176) | 0.5876 |
CL/F, L/hr | 41.1 | 38.0 | 1.082 (0.850–1.376) | 0.5884 |
ANAM: anamorelin; AUC0-24,ss: area under the concentration-time curve from time zero to 24 hours at steady state; AUCinf: area under the concentration-time curve from time zero to infinity; AUCinf/dose: area under the concentration-time curve from time zero to infinity normalized for the dose-per-kg body weight; CI: confidence interval; CL/F: clearance; Cmax: maximum plasma concentration; Cmax/dose: maximum plasma concentration normalized for the dose-per-kg body weight; Cmax,ss: steady-state maximum plasma concentration; LS: least squares; NSCLC: non-small cell lung cancer; PK: pharmacokinetic; t1/2,z: elimination half-life; tmax: time to maximum plasma concentration; SD: standard deviation; Vz/F: volume of distribution.
Conclusions
No significant gender effect on ANAM PK/PD was observed in healthy volunteers and NSCLC patients with cachexia at 100 mg ANAM, intended for therapeutic use.
Clinical trial identification
ROMANA 3: NCT01387269.
Editorial acknowledgement
Oana Draghiciu, PhD, CMPP, from Aptitude Health, The Hague, The Netherlands; funded by Helsinn Healthcare SA.
Legal entity responsible for the study
Helsinn Healthcare SA.
Funding
Helsinn Healthcare SA.
Disclosure
S. Kaasa: Shareholder / Stockholder /Stock options: Eir Solution, Research grant / Funding: Nutricia, Research grant / Funding: Recipient, Honoraria: Fresenius Kabi, Honoraria: Nutricia. J.M. Garcia: Research grant / Funding: Helsinn Healthcare SA. A. Bernareggi: Full / Part-time employment: Helsinn Healthcare SA.
Resources from the same session
4242 - HIV, HBV and HCV screening practices in oncology: a cross-sectional interregional survey
Presenter: Isabelle Poizot-Martin
Session: Poster Display session 1
Resources:
Abstract
1267 - Genetic landscape of KEAP1 and NFE2L2 mutated cancers from the AACR GENIE database
Presenter: Mark Zaki
Session: Poster Display session 1
Resources:
Abstract
878 - β-arrestin1 is involved in the Ras-induced malignant transformation
Presenter: Takashi Shibano
Session: Poster Display session 1
Resources:
Abstract
4143 - Incidence of second cancer among PLWHIV: retrospective observational study of a series of 601 patients in the French CANCERVIH network
Presenter: Jean-Philippe Spano
Session: Poster Display session 1
Resources:
Abstract
5145 - A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: the CUPISCO trial experience
Presenter: Chantal Pauli
Session: Poster Display session 1
Resources:
Abstract
1737 - Incidence and Outcome of chronic lymphocytic leukemia with Deletion 17p: An Indian experience; challenges and opportunities
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
2596 - Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia
Presenter: Jonathan Killian
Session: Poster Display session 1
Resources:
Abstract
1499 - The potential of a novel antiangiogenic VEGFR1-D2 binding peptide in oncology therapeutics
Presenter: Afsaneh Sadre Momtaz
Session: Poster Display session 1
Resources:
Abstract
1775 - First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
Presenter: Mayu Yunokawa
Session: Poster Display session 1
Resources:
Abstract
4584 - First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumors: Dose-optimization cohorts
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract